Phaseline

Companies › Longeveron

Longeveron: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lomecel-B
Allogeneic human mesenchymal stem cells (MSCs) from bone marrow with signaling capacity
–Phase 2Hypoplastic Left Heart Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04925024Lomecel-BPhase 2Hypoplastic Left Heart SyndromeOtherJun 2026

From the company's SEC filings

Cash of $10m on 2026-06-30; operating cash outflow about $20m a year; runway about 6 months at that burn, to Dec 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg Intervene Immune Biosolution

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.